The Conversation (0)
Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme
Jun. 29, 2018 08:54AM PST
Medical Device Investing
Agilent Technologies (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme a leading provider of glycan analysis reagents, kits and standards. This acquisition will expand Agilent’s portfolio of biopharma consumables in the fast-growing glycan market. As quoted in the press release: “Agilent is focused on being a complete workflow …
Agilent Technologies (NYSE: A) today announced that it has entered into a definitive agreement to acquire privately-held ProZyme a leading provider of glycan analysis reagents, kits and standards. This acquisition will expand Agilent’s portfolio of biopharma consumables in the fast-growing glycan market.
As quoted in the press release:
“Agilent is focused on being a complete workflow solutions provider,” said Mark Doak, president of Agilent’s CrossLab Group. “We have a strong installed base of customers worldwide, and expanding our consumables portfolio is key to our strategy of providing a seamless customer experience and helping our customers reduce the cost and time required to bring new therapeutics to market.”
Founded in 1990, ProZyme is an industry leading developer and manufacturer of glycan reagents, kits and standards, which are required for efficient sample prep in the analysis of free glycans. Glycobiology, which is the study of the structure, function and biology of carbohydrates, also called glycans, is a fast-growing and important field of study in life sciences. Glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.
